Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
$146.00 8 in stock 8 in stock This product is intended for laboratory research use only
Gastrointestinal adverse events, mostly mild or moderate, were more frequent in the treatment group (72.5%) than in the placebo group (34.4%)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Enhanced delivery systems such as microemulsions show 3-fold improved efficacy in animal models
US$ 25.25
US$ 21.05
US$ 21.66
US$ 26.15
US$ 28.70
US$ 28.41
US$ 29.11
US$ 21.14
US$ 22.18
US$ 21.81
US$ 26.95
US$ 26.51
US$ 20.30
US$ 24.77
US$ 24.32
US$ 19.99
